Detection of Tumor‐Specific Variants in CSF of Children With Brain Tumors, Including Low‐Grade and Cytology‐Negative Cases
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Kenichi Usami und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurosurgery, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Brain Neoplasms, Biomarkers, Tumor, Circulating Tumor DNA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
The genetic diagnosis of brain tumors necessitates the direct collection of tumor tissue. Recently, genetic diagnosis using cell‐free DNA (cfDNA) from plasma has been clinically applied to some somatic cancers, but it has not been established for brain tumors. This study conducted a genetic diagnosis via liquid biopsy (LB) using cfDNA extracted from the plasma and cerebrospinal fluid (CSF) of pediatric brain tumor patients.
Methods
The study included children who underwent surgical resection or biopsy for brain tumors between January 2019 and December 2020. Tumor‐specific variants were identified using whole‐exome sequencing of genomic DNA from tumor samples and normal blood cells. Subsequently, CSF and plasma collected during surgery were analyzed for these specific variants using droplet digital PCR.
Results
Tumor‐specific variants were detected in six of 13 (46.2%) CSF samples. In contrast, no tumor‐specific variants were detected in plasma in any patient. Among the six CSF‐positive cases, two had negative or inconclusive CSF cytology (Class I or II), and one was a case of low‐grade pilocytic astrocytoma. The median variant allele frequency in the positive CSF samples was 16.0% (range: 0.6%–86.1%).
Conclusion
In certain pediatric brain tumors, genetic diagnosis using cfDNA from CSF demonstrated promising potential. This approach has the potential for diagnosis in cases with negative cytology or low‐grade tumors. However, several issues must be addressed before this method can achieve clinical utility, including its low sensitivity and the extended turnaround time for analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurosurgery, National Center for Child Health and Development, Tokyo, Japan.
- Department of Pediatric Hematology and Oncology Research, National Center for Child Health and Development, Tokyo, Japan.
- Department of Pathology, National Center for Child Health and Development, Tokyo, Japan.
- Division of Neuro-Oncology, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
ORCID-Profile: Kenichi Usami
Zitieren
APA
Usami, K., Mizuno, T., Shirai, R., Yoshioka, T., Terashima, K., Kiyotani, C., Ogiwara, H., & Kato, M. (2026). Detection of Tumor‐Specific Variants in CSF of Children With Brain Tumors, Including Low‐Grade and Cytology‐Negative Cases. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70069
Vancouver
Usami K, Mizuno T, Shirai R, Yoshioka T, Terashima K, Kiyotani C, et al. Detection of Tumor‐Specific Variants in CSF of Children With Brain Tumors, Including Low‐Grade and Cytology‐Negative Cases. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70069
BibTeX
@article{Usami2026,
author = {Usami, Kenichi and Mizuno, Takanori and Shirai, Ryota and Yoshioka, Takako and Terashima, Keita and Kiyotani, Chikako and Ogiwara, Hideki and Kato, Motohiro},
title = {Detection of Tumor‐Specific Variants in CSF of Children With Brain Tumors, Including Low‐Grade and Cytology‐Negative Cases},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70069}
}
EUVIMED